Cell Kinetics Extends Expiration Date of Rights Offering to January 7, 2008.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Cell Kinetics Ltd., an indirect, wholly-owned subsidiary of Medis Technologies Ltd. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : MDTL MDTL Medis Technologies, Ltd (stock symbol) MDTL Montana Defense Trial Lawyers Association ), announced today the extension of the expiration date Expiration Date The day on which an options or futures contract is no longer valid and, therefore, ceases to exist. Notes: The expiration date for all listed stock options in the U.S. of Cell Kinetics' rights offering (the "Rights Offering") to January 7, 2008 to allow for the completion of certain state securities or "blue sky law" qualifications of the Rights Offering. Cell Kinetics has distributed to record holders of Medis' outstanding common stock, at no cost, nontransferable subscription rights to purchase up to an aggregate of 3,505,337 of Cell Kinetics' ordinary shares, at a subscription price of $0.30 per share. Record holders of Medis' common stock received one subscription right for every ten shares of Medis' common stock held by them as of the close of business on the record date, which was November 12, 2007. Medis record holders who purchase Cell Kinetics' ordinary shares in the Rights Offering will also receive four year warrants to purchase additional Cell Kinetics ordinary shares, at an exercise price of $0.60 per share, at the rate of one such warrant for every two ordinary shares purchased in the Rights Offering. The Rights Offering was originally scheduled to expire at 5:00 p.m., New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. time, on December 17, 2007. The new expiration date for the Rights Offering is 5:00 p.m., New York City time, on January 7, 2008, unless extended. Copies of the prospectus relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the Rights Offering may be obtained by calling (212) 935-8484. A copy of the prospectus is also available through the SEC's Internet website, located at http://www.sec.gov. Cell Kinetics intends to commercialize Medis' Cell Carrier, which Cell Kinetics intends to market under the "CKChip[TM]" tradename, and related technology. Cell Kinetics also intends to source, vet and invest in early stage Israeli-based medical device companies. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of such rights or common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. This press release may contain forward-looking statements, which are made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements involve risk and uncertainties, including, but not limited to, the successful completion of product development, the success of product tests, commercialization risk, availability of financing and results of financing efforts. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion